Prognostic Value of Dipyridamole Stress Cardiovascular Magnetic Resonance Imaging in Patients With Known or Suspected Coronary Artery Disease
Vicente Bodi, MD, FESC*,*,
Juan Sanchis, MD, FESC*,
Maria P. Lopez-Lereu, MD ,
Julio Nunez, MD*,
Luis Mainar, MD*,
Jose V. Monmeneu, MD,
Oliver Husser, MD*,
Eloy Dominguez, MD*,
Francisco J. Chorro, MD, FESC* and
Angel Llacer, MD, FESC*
* Cardiology Department, University Clinic Hospital, University of Valencia, Valencia, Spain
Exploraciones Radiológicas Especiales Sociedad Anónima, Valencia, Spain.
View larger version (157K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Dipyridamole Stress CMR Allows Assessment of AWM-rest and -D, Perfusion Deficit, and Delayed Enhancement
Example of a patient with stress-induced systolic dysfunction and perfusion deficit in the inferior area (arrows) and a small area of delayed enhancement in the anterior territory (bottom right panel, arrow). AWM-D = abnormal wall motion with dipyridamole; AWM-rest = abnormal wall motion at rest; CMR = cardiovascular magnetic resonance imaging.
Please see the Appendix for accompanying video.
|
|
View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 MACE and Major Events Depending on the Presence or Absence of Abnormal ( 1 Segment) Stress Dipyridamole CMR Indexes in the Whole Group
AWM-D = number of segments with abnormal wall motion with dipyridamole; AWM-rest = number of segments with abnormal wall motion at rest; CMR = cardiovascular magnetic resonance imaging; MACE = major adverse cardiac events.
|
|
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Kaplan-Meier Survival Distributions Without MACE Based on the Presence or Absence of Abnormal Wall Motion With Dipyridamole
(Top) Unadjusted curves; (bottom) survival curves adjusted for diabetes, hypertension, and previous infarction; (left) whole group; (right) nonrevascularized patients. Dashed lines = presence (1 segment) of abnormal wall motion with dipyridamole; solid lines = absence (0 to 1 segment) of abnormal wall motion with dipyridamole. AWM-D = number of segments with abnormal wall motion with dipyridamole; MACE = major adverse cardiac events.
|
|
|
